Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th
March 22 2022 - 9:00AM
Artelo Biosciences, Inc. (Nasdaq:
ARTL), a clinical stage pharmaceutical company developing
therapeutics that modulate lipid-signaling pathways, including the
endocannabinoid system, today announced it has been invited to
present at the 2022 Virtual Growth Conference, presented by Maxim
Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m.
- 5:00 p.m. EDT.
The conference will feature roundtable
discussions, fireside chats, and multiple company presentations,
including a corporate update from Gregory Gorgas, President and
CEO, Artelo Biosciences. Also during this virtual conference,
investors will hear from other biotech executives and leaders from
a wide range of sectors. Those who wish to attend must first sign
up to become an M-Vest member.
Sign up here to access the presentation.
About Artelo BiosciencesArtelo
Biosciences, Inc. is a clinical stage pharmaceutical company
dedicated to the development and commercialization of proprietary
therapeutics that modulate lipid-signaling pathways, including the
endocannabinoid system. Artelo is advancing a portfolio of broadly
applicable product candidates designed to address significant unmet
needs in multiple diseases and conditions, including anorexia,
cancer, PTSD, pain, and inflammation. Led by proven pharmaceutical
executives collaborating with highly respected researchers and
technology experts, Artelo applies leading edge scientific,
regulatory, and commercial discipline to develop high-impact
therapies. More information is available
at www.artelobio.com and Twitter: @ArteloBio.
Forward Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to Artelo’s product development,
clinical and regulatory timelines, market opportunity, competitive
position, possible or assumed future results of operations,
business strategies, potential growth opportunities and other
statement that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts
and projections about the industry and markets in which we operate
and management’s current beliefs and assumptions. These statements
may be identified by the use of forward-looking expressions,
including, but not limited to, “expect,” “anticipate,” “intend,”
“plan,” “believe,” “estimate,” “potential,” “predict,” “project,”
“should,” “would” and similar expressions and the negatives of
those terms. These statements relate to future events or our
financial performance and involve known and unknown risks,
uncertainties, and other factors which may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements. Such factors include those set
forth in Artelo’s filings with the Securities and Exchange
Commission, including our ability to raise additional capital in
the future. Prospective investors are cautioned not to place undue
reliance on such forward-looking statements, which speak only as of
the date of this press release. Artelo undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by applicable securities laws.
Investor Relations
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ARTL@crescendo-ir.com
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Artelo Biosciences (NASDAQ:ARTL)
Historical Stock Chart
From Apr 2023 to Apr 2024